Infection News

Gavi, the Vaccine Alliance forecasted that the global supply of oral cholera vaccine is likely to remain limited through 2025 if current outbreak trends continue.

According to HHS, many of the more than 3.2 million people in the United States with hepatitis B or C are not aware of their infection, raising their risk for severe complications or death and risking further spread of the viruses.

CHICAGO — In a Healio video exclusive, Glenn S. Tillotson, MSc, PhD, discusses the safety and sustained efficacy of Rebyota at 6 months for recurrent Clostridioides difficile infection in patients with immunocompromising conditions.

CHICAGO — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, recaps results from a real-world analysis of Zinplava for prevention of recurrent Clostridioides difficile infection in patients with congestive heart failure.

CHICAGO — In this Healio video, Evan S. Dellon, MD, MPH, explains that while mepolizumab outperformed placebo at 3 months, there were no additional symptom or endoscopic improvements at 6 months in patients with eosinophilic esophagitis.

An outbreak of Shiga toxin-producing Escherichia coli in Tennessee was caused by raw milk consumption among members of a cow-share, according to a study.

CHICAGO — Treatment with Rebyota did not affect concurrent medication use in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection, Jessica R. Allegretti, MD, MPH, explains in this Healio video.

CHICAGO — In a Healio video exclusive, Ken Blount, PhD, discusses successful restoration of gut microbiota and clonal engraftment as soon as 1 week after treatment with Rebyota in those with recurrent Clostridioides difficile infection.

CHICAGO — In a Healio video exclusive, Jessica R. Allegretti, MD, MPH, explains that nearly 23% of patients with moderate to severe ulcerative colitis achieved clinical remission with Tremfya, compared with less than 10% on placebo.

CHICAGO — More than 20% of patients with inflammatory bowel disease experienced recurrent Clostridioides difficile infection 1 year after fecal microbiota transplantation, according to data presented at Digestive Disease Week.